Vaxcyte (PCVX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PCVX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares crossed below its 50 day moving average during trading on Monday after an insider sold shares in the company. The stock has a 50 day moving average of $62.25 and trad…

Candriam S.C.A. increased its holdings in Vaxcyte, Inc. (NASDAQ: PCVX) by 115.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 447,260 sha…

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 A…

The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earning…

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst h…

The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings…

What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 million of 1.50% convertible senior notes due 2032. The notes are senior unsecured obligations. The initial conversion rate …

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total transact…

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares…

Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS…

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday after Needham and Company LLC raised their price target on the stock from $110.00 to $122.00. Needham and Company LLC c…

Vaxcyte (NASDAQ: PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults. The randomized, do…

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its …

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript…

Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-sta…

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 2,615 call options on the stock. This represents an increase of approximately 17% compared to the av…

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.…

Shares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) reached a new 52-week high on Monday. The company traded as high as $89.00 and last traded at $87.1950, with a volume of 1927060 shares trading hands. The stock ha…

Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.…

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)…

SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:0…

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.…

California State Teachers Retirement System boosted its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 5,915.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 3,549 put options on the company. This is an increase of approximately 52% compared to…

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar…

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

